Improving outcomes in myeloid leukemia patients: does a new DNA vaccine hold the answer?

References

• Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med.300(19), 1068–1073 (1979).
   PubMed Web of Science ®Google Scholar
• Gao L, Bellantuono I, Elsasser A et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood95(7), 2198–2203 (2000).
   PubMed Web of Science ®Google Scholar
• Oka Y, Elisseeva OA, Tsuboi A et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms’ tumor gene (WT1 ) product. Immunogenetics51(2), 99–107 (2000).
   PubMed Web of Science ®Google Scholar
• Inoue K, Sugiyama H, Ogawa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood84(9), 3071–3079 (1994).
   PubMed Web of Science ®Google Scholar
• Gannage M, Abel M, Michallet AS et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J. Immunol.174(12), 8210–8218 (2005).
   PubMed Web of Science ®Google Scholar
• Rezvani K, Grube M, Brenchley JM et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood102(8), 2892–2900 (2003).
   PubMed Web of Science ®Google Scholar
• Rezvani K, Brenchley JM, Price DA et al. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms’ tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin. Cancer Res.11(24 Pt 1), 8799–8807 (2005).
   PubMed Web of Science ®Google Scholar
• Scheibenbogen C, Letsch A, Thiel E et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood100(6), 2132–2137 (2002).
   PubMed Web of Science ®Google Scholar
• Yong AS, Keyvanfar K, Eniafe R et al. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia22(9), 1721–1727 (2008).
   PubMedGoogle Scholar
• Elisseeva OA, Oka Y, Tsuboi A et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood99(9), 3272–3279 (2002).
   PubMed Web of Science ®Google Scholar
• Wu F, Oka Y, Tsuboi A et al. Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies. Leukemia19(2), 268–274 (2005).
   Google Scholar
• Rezvani K, Yong AS, Savani BN et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood110(6), 1924–1932 (2007).
   PubMed Web of Science ®Google Scholar
• Keilholz U, Letsch A, Busse A et al. A clinical and immunologic Phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood113(26), 6541–6548 (2009).
   PubMed Web of Science ®Google Scholar
• Maslak PG, Dao T, Krug LM et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood116(2), 171–179 (2010).
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA101(38), 13885–13890 (2004).
   PubMed Web of Science ®Google Scholar
• Rezvani K, Yong AS, Mielke S et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood111(1), 236–242 (2008).
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Van de Velde A, Van Driessche A et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl Acad. Sci. USA107(31), 13824–13829 (2010).
   PubMed Web of Science ®Google Scholar
• Rezvani K, Yong ASM, Mielke S et al. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica96(3), 432–440 (2011).
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Ottensmeier CH, Rice J. DNA vaccines against cancer come of age. Curr. Opin. Immunol.22(2), 264–270 (2010).
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Ottensmeier CH, Johnson P et al. DNA vaccines to attack cancer. Proc. Natl Acad. Sci. USA101(Suppl. 2), 14646–14652 (2004).
   PubMed Web of Science ®Google Scholar
• Chaise C, Buchan SL, Rice J et al. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood112(7), 2956–2964 (2008).
   PubMed Web of Science ®Google Scholar